Korean J Dermatol.
2006 Mar;44(3):304-308.
Expression of Smad 2 and 3 on the Lesions of Leprosy
- Affiliations
-
- 1Department of Dermatology, College of Medicine, Inha University, Incheon, Korea. jshin@inha.ac.kr
- 2Department of Dermatology, College of Medicine, Ewha Womans University, Seoul, Korea.
Abstract
-
BACKGROUND: Leprosy is an infectious disease with two polar forms, tuberculoid leprosy (TT) and lepromatous leprosy (LL), that are characterized by strong cell-mediated immunity (CMI) and CMI anergy, respectively. Transforming growth factor-beta (TGF-beta) is a family of growth factors involved in essential physiological processes, including development, differentiation, tissue repair, cell growth control and inflammation. Cellular signaling by TGF-beta family members is initiated by the assembly of specific cell surface receptors that activate transcription factors of the Smad family. Deregulation of the TGF-beta-Smad signaling pathway has been implicated in developmental disorders and several human diseases. Recently, ELISA & immunohistochemistry revealed high expression of TGF-beta isoforms in LL.
OBJECTIVE
The purpose of this study was to investigate TGF-beta-Smad signaling in various forms of leprosy.
METHODS
We investigated the involvement of TGF-beta by immunohistochemical staining for Smad 2 and 3 in skin biopsies from six patients of BL and four patients of TT.
RESULTS
The inflammatory cells, keratinocytes and fibroblasts in BL showed strong positivity for both Smad 2 and 3, whereas those in TT showed little positivity.
CONCLUSION
The high expression of Smad 2/3 in BL could represent high expression of TGF-beta, which possibly contributes to local CMI anergy and other clinical characteristic features of leprosy.